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Mice lacking functional neurokinin-1 receptors (NK1R/) display behavioural abnormalities
resembling attention deﬁcit hyperactivity disorder (ADHD): locomotor hyperactivity, impulsivity
and inattentiveness. The preferred ligand for NK1R, substance P, is metabolised by angiotensin
converting enzyme (ACE), which forms part of the brain renin angiotensin system (BRAS). In
view of evidence that the BRAS modulates locomotor activity and cognitive performance, we
tested the effects of drugs that target the BRAS on these behaviours in NK1R/ and wildtype
mice. We ﬁrst tested the effects of the ACE inhibitor, captopril, on locomotor activity. Because
there are well-established sex differences in both ADHD and ACE activity, we compared the
effects of captopril in both male and female mice. Locomotor hyperactivity was evident in male
NK1R/ mice, only, and this was abolished by treatment with captopril. By contrast, male
wildtypes and females of both genotypes were unaffected by ACE inhibition. We then
investigated the effects of angiotensin AT1 (losartan) and AT2 (PD 123319) receptor antagonists
on the locomotor activity of male NK1R/ and wildtype mice. Both antagonists increased the
locomotor activity of NK1R/ mice, but neither affected the wildtypes. Finally, we tested
the effects of captopril on the performance of male NK1R/ and wildtype mice in the
5-choice serial reaction-time task (5-CSRTT) and found that ACE inhibition prevented the
impulsivity of NK1R/ mice. These results indicate that certain behaviours, disrupted ino.2015.01.013
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/by/4.0/).
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513The angiotensin converting enzyme inhibitor, captopril,ADHD, are inﬂuenced by an interaction between the BRAS and NK1R, and suggest that ACE
inhibitors could provide a novel treatment for this disorder.
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Male mice with functional ablation of the Nk1r gene, which
encodes the substance P-preferring NK1 receptor (NK1R/),
express locomotor hyperactivity in several experimental con-
texts (Fisher et al., 2007; Herpfer et al., 2005; Yan et al., 2010).
In the 5-choice serial reaction-time task (5-CSRTT), a procedure
that is used to evaluate cognitive performance, NK1R/ mice
also express more omissions (inattentiveness) and more pre-
mature responses (motor impulsivity) compared with their
wildtypes (Dudley et al., 2013; Yan et al., 2011). Hyperactivity,
inattentiveness and impulsivity are diagnostic criteria for atten-
tion deﬁcit hyperactivity disorder (ADHD). On this basis, and
supported by evidence from human genetic studies (Sharp et al.,
2014), we have proposed that polymorphism(s) of the TACR1
gene (the human equivalent of the mouse Nk1r gene) could be
associated with increased risk of developing ADHD.
Studies in vitro have shown that substance P is degraded by
angiotensin converting enzyme (‘ACE’: peptidyl dipeptidase A;
EC 3.4.15.1; Skidgel et al., 1984), which forms part of the brain
renin angiotensin system (BRAS). It is still not certain that ACE
metabolises substance P in vivo (Mitchell et al., 2013) and, in
any case, ACE is not the only peptidase that metabolises this
peptide (Oblin et al., 1988). Nevertheless, a substantial body
of evidence indicates that the BRAS regulates both locomotor
activity and executive function (for recent review, see: Wright
and Harding, 2011). For instance, ACE inhibitors improve
performance in several preclinical screens of learning and
memory, such as the Morris water maze and tests of active/
passive avoidance (e.g., Barnes et al., 1992; Nikolova et al.,
2000). ACE inhibitors also enhance cognitive performance in
hypertensive patients and healthy controls, as well as in
patients with dementia (Croog et al., 1986; Currie et al.,
1990; Rozzini et al., 2006). Moreover, histochemical markers
indicate that the BRAS is distributed across neuronal networks
that have been strongly implicated in ADHD and motor control.
For example, both ACE and angiotensin (AT) receptors are
densely expressed within the basal ganglia, in regions such as
the dorsal striatum, globus pallidus and substantia nigra
(Strittmatter et al., 1984; Chai et al., 1987; Allen et al., 1992).
We reasoned that if ACE degrades substance P in vivo,
then inhibition of this enzyme would reduce locomotor
activity of wildtypes but would not affect NK1R/ mice
because they lack functional NK1R. Even if substance P
fragments bind to and activate other sites, inhibition of ACE
should modify the locomotor activity of wildtype and
NK1R/ mice in different ways. To test this possibility,
we compared the locomotor activity of male NK1R/
mice and their wildtypes in a light/dark exploration box
(LDEB) following administration of the ACE inhibitor, capto-
pril. Unlike many ACE inhibitors, this compound penetrates
the brain in its active form (Geppetti et al., 1987; Ranadive
et al., 1992). A caveat to this experiment was prompted byreports that ADHD, especially of the predominantly hyper-
active/impulsive subtype, is more common in boys than girls
(Waddell and McCarthy, 2012). There is also a report
suggesting sex differences in ACE activity, which is reduced
by oestrogen (Komukai et al., 2010). In light of this
evidence, we compared the effects of captopril on the
locomotor activity of both male and female NK1R/ mice
and their wildtype counterparts.
Contrary to our prediction, treatment with captopril reduced
the locomotor activity of male NK1R/ mice but did not
affect that of male wildtypes, or female mice of either
genotype. Given that ACE is better known for converting the
(presumed) inactive precursor, angiotensin I, to the active
product, angiotensin II (AngII), an obvious possibility is that this
behavioural response to captopril could be due to a deﬁcit in
angiotensin II production. If so, this response should be mimi-
cked by drug antagonism of AngII (type 1 (AT1) and/or type 2
(AT2)) receptors, which are expressed by neurones and glial
cells in subcortical regions, including the striatum (Allen et al.,
1992). To investigate this proposal, we compared the locomotor
response of the two genotypes after treatment with either a
selective AT1 receptor antagonist (losartan) or AT2 receptor
antagonist (PD 123319).
Finally, there is extensive evidence that the BRAS modulates
cognitive performance. For instance, several early studies
suggested that captopril could have nootropic actions in rodents
(e.g., Earley et al., 1989; Mondadori and Etienne, 1990; see:
Wright and Harding, 2011). Against this background, a third
experiment compared the effects of captopril on the cognitive
performance and response control of male NK1R/ and
wildtype mice in the 5-CSRTT. We used this protocol because
NK1R/ mice have previously demonstrated both increased
premature responses (an index of one form of impulsivity) and
increased omissions (an index of inattentiveness) in this test
(Dudley et al., 2013; Yan et al., 2011). Furthermore, it has been
concluded, from a battery of studies measuring impulsivity in
ADHD patients, that premature responses are “…the most
sensitive measures for discriminating ADHD from control chil-
dren” (Rubia et al., 2007). Consequently, the measurement of
premature responses by NK1R/ mice in the 5-CSRTT has
strong translational relevance for ADHD research.
2. Experimental procedures
These experiments were authorised under the UK Animals (Scien-
tiﬁc Procedures) Act 1986 and received approval from the local
Animal Welfare and Ethical Review Body (UCL). This report complies
with the ARRIVE guidelines for reporting of animal experiments.
2.1. Animals
All the animals were from inbred colonies maintained at University
College London. NK1R/ mice and their wildtype counterparts
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outbred MF1 strain many generations ago (described fully in: de
Felipe et al. 1998). Animals were housed (2–5 mice per cage) in a
holding room at 2172 1C, 4575% humidity, with a 12:12 h light:
dark cycle (lighting increased in steps from 07.00 to 08.00 h and
reduced in steps from 19.00 to 20.00 h). The home-cages incorpo-
rated environmental enrichment and sawdust bedding (3Rs Bedding
Pty, Ltd) and were cleaned twice weekly. Water and food (2018
global Rodent Diet (Harlan)) were freely available for mice that
were used to monitor locomotor activity, but mice destined for the
5-CSRTT were subjected to a restricted diet (see below).
2.2. Drugs
Captopril (N-[(S)-3-mercapto-2-methylpropionyl]-L-proline) was pur-
chased from Sigma Aldrich, UK, losartan potassium (2-butyl-4-chloro-
1-[[20-(1H-tetrazol-5-yl)[1,10-biphenyl]-4-yl]methyl]-1H-imidazole-5-
methanol monopotassium salt) was purchased from LKT laboratories,
UK, and PD 123319 ditriﬂuoroacetate (1-[[4-(dimethylamino)-3-
methylphenyl]methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imi-
dazo[4,5-c]pyridine-6-carboxylic acid ditriﬂuoroacetate) was pur-
chased from Tocris, UK. All drugs were dissolved in 0.9% saline
and administered by intraperitoneal (i.p.) injection in a volume of
10 mL/kg. The choice of doses was informed by published reports
conﬁrming a physiological or behavioural response to these drugs in
mice and/or rats in vivo (e.g., captopril: Raghavendra et al., 2001;
losartan: Vijayapandi and Nagappi, 2005; PD 123319: Macova et al.,
2009).
2.3. Experimental design
2.3.1. Experiment 1: Effects of captopril on locomotor activity
of male and female NK1R/ and wildtype mice
Male and female wildtype and NK1R/ mice were used (i.e., four
groups, N=6 for each group). They were 6–11 weeks of age and
weighed 20–37 g. Animals were selected from a total of nine
breeding pairs per genotype and selected to age-match the four
groups as closely as possible.
Animals’ locomotor activity was monitored using a light/dark
exploration box (LDEB; described fully in: Yan et al., 2010). Brieﬂy,
the mice were brought into the laboratory and weighed at 09.30 h
and allowed to habituate to the test room for at least 3 h. At
13.00 h, they were placed into the dark zone of the LDEB and, after
60 min habituation, received a randomly assigned intraperitoneal
(i.p.) injection of either captopril (10 or 25 mg/kg), or vehicle
control (0.9% saline) or they were left untreated (no injection,
‘NI’). After a further 30 min (i.e., a total of 90 min in the dark
zone), animals were transferred to the light zone of the LDEB and
allowed free movement across both zones for 30 min. Their
behaviour was recorded digitally and scored ‘blind’, later.
2.3.2. Experiment 2: Effects of AT1 and AT2 receptor
antagonism on locomotor activity of male NK1R/ and
wildtype mice
Because hyperactivity and a response to captopril were evident only
in male NK1R/ mice, female mice were not used in this
experiment. When testing losartan, the male mice were 6–10 weeks
of age (25–41 g; N=6 per group). A separate batch of mice was used
to test the effects of PD 123319, and were 7-12 weeks of age (29-
40 g; N=5 per group). In both cases, animals were selected from
eight to nine different breeding pairs per genotype and selected so
as to age-match the groups as closely as possible.
The protocol was similar to that used in experiment 1. One batch
of animals received a randomly-assigned injection of either losartan
(10 or 25 mg/kg, i.p.) or vehicle (0.9% saline, i.p.) following 30 min
habituation to the dark zone of the LDEB. In a second batch ofanimals, losartan was replaced by PD 123319 (1 or 3 mg/kg, i.p.).
All animals were transferred to the light zone 60 min after injection
(i.e., a total of 90 min in the dark zone) and allowed free move-
ment across both zones for 30 min. Their behaviour was recorded
digitally and scored ‘blind’, later.
2.3.3. Experiment 3: Effects of captopril on the performance
of male NK1R/ and wildtype mice in the 5-choice serial
reaction-time task
Again, because a response to captopril was evident only in male
NK1R/ mice, this experiment did not study females. The males
were aged 6–7 weeks and weighed 23–33 g at the start of testing
(N=12 per group). Animals were selected from a total of three
separate breeding pairs per genotype and were age-matched as
closely as possible.
The protocol is described fully in Yan et al. (2011). All animals were
subject to restricted food intake in order to stabilise their body weight
at 90% of their free-feeding weight. Animals were brought to the
laboratory between 09.00 and 09.30 h Monday to Friday, and trained/
tested in the 5-CSRTT in either a morning session (10.00–12.00 h) or
afternoon session (13.00–15.00 h). An equal number of wildtypes and
NK1R/ mice were balanced across the morning and afternoon
sessions. Following habituation to the apparatus, animals were trained
to nose-poke in response to a light stimulus that appeared in one of ﬁve
equally spaced nose-poke apertures on one of the walls of the 5-CSRTT
chamber. A correct response (nose-poking in the correct hole within the
limited time-frame) triggered delivery of a sweetened milk reward
(0.01 mL of 30% condensed milk solution) from a magazine in the
opposite wall of the chamber. An incorrect response (nose-poking into a
hole other than that signalled by the light stimulus), or an omission
(failing to respond), or a premature response all resulted in a ’time-out’
punishment (i.e., the house-light of the apparatus was turned off and no
reward was provided).
Animals were required to graduate through a series of six training
stages before testing. The training stages were made progressively
more difﬁcult by: increasing the length of time before the light
stimulus appears (intertrial interval, ‘ITI’); decreasing the length of
time the animal has to respond to the light stimulus (limited hold,
‘LH’); decreasing the duration of the light stimulus (stimulus
duration, ‘SD’). To achieve the baseline for testing, the animals
were required to achieve speciﬁc performance criteria based on: the
total number of trials completed; the number of correct responses
completed; %accuracy; and %omissions (see: Yan et al., 2011).
Once the mice had attained stable baseline performance (100
completed trials,450 correct trials,475% accuracy,o25% omissions),
untreated (uninjected) subjects were tested using two different test
sessions: a long intertrial interval (LITI) test, which increases the ITI
from 5 s to 10 s, and a variable intertrial interval (VITI) test, in which
the ITI is variable (2, 5, 10 and 15 s) and delivered on a random
schedule.
Animals experienced a series of once-weekly tests following either
a second test with no injection (‘NI’), to serve as the baseline for the
series of tests, a vehicle injection (0.9% saline, 10 mL/kg, i.p.), or
captopril injection (5, 10 or 25 mg/kg, i.p.). All ﬁve treatments (NI,
vehicle and captopril (3 doses)) were tested with both the VITI and
LITI (10 testing sessions in total). Every animal experienced each test
condition once, only, in a sequence that was counterbalanced
(William’s Latin-square) across both experimental factors (genotype
and time-of-day). All testing was carried out on Fridays, only. On
intervening days, animals repeated Stage 6 of training, to ensure that
stable baseline performance criteria were re-established before the
next test.
2.4. Statistical analysis
The software package InVivoStat (Clark et al., 2012) was used for all
statistical analyses, which were carried out on raw data unless
Fig. 1 Sex differences in the locomotor activity of (unin-
jected) wildtype and NK1R/ mice in the light/dark
exploration box. Locomotor activity, measured as ‘Speed in
Light Zone’ (LZ; lines crossed/time) (A). Time in LZ (B). Latency
to leave LZ (C). Latency to ﬁrst return to LZ (D). Number of
returns to LZ (E). Bars indicate mean7s.e.m. Lines indicate
statistically signiﬁcant differences between groups. * Po0.05,
** Po0.01, *** Po0.001. N=6 per group. Data were analysed
using single measures two-way ANOVA followed by post hoc
(LSD) pair-wise comparisons.
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variance of the samples suggested that transformation (square-root
(score) or Log10(score+1)) was necessary.
In the LDEB experiments, data were analysed using a multi-
factorial 3-way single measures ANOVA with ‘genotype’, ‘treatment’
and ‘sex’ as between-subjects factors. In the 5-CSRTT experiment,
data were analysed using a repeated measures (mixed model) ANOVA
with ‘genotype’ and ‘time-of-day’ as the between-subjects factors
and ‘treatment’ as the within-subjects factor. For both experiments,
a signiﬁcant effect of one of the main factors, or an interaction
between them, was used as the criterion for progressing to post-hoc
(LSD) comparisons.
3. Results
3.1. The hyperactivity of uninjected NK1R/
mice is evident in male animals, only
In line with previous reports, the locomotor activity of male
NK1R/ mice was greater than that of male wildtype
mice (LSD: Po0.001; Fig. 1A). We now further report that
this hyperactivity of NK1R/ mice depends on their sex
(genotype sex interaction: F(1,20)=7.41, P=0.013). Not
only was the locomotor activity of male NK1R/ mice
greater than that of their female counterparts (LSD:
P=0.033), but the locomotor activity of female mice did
not differ in the two genotypes (LSD: P=0.074).
NK1R/ mice spent less time in the light zone (main
effect of genotype: F(1,22)=27.77, Po0.001; Fig. 1B) and
took longer to ﬁrst return to the light zone (an index of
passive avoidance; main effect of genotype: F(1,22)=11.22,
P=0.003; Fig. 1D) compared with wildtype mice. However,
the two genotypes did not differ in either their latency to
leave the light zone (an index of active avoidance; Fig. 1C)
or the number of returns to the light zone (Fig. 1E). None of
these behaviours differed in males and females (Fig. 1B–E).
3.2. The ACE inhibitor, captopril, reduces
locomotor activity of male NK1R/ mice, only
Both doses of captopril reduced the locomotor activity of
male NK1R/ mice, abolishing their hyperactivity (LSD
(cf., vehicle): P=0.05 (10 mg/kg) and P=0.006 (25 mg/kg);
Fig. 2A). However, neither dose affected the locomotor
activity of either male wildtype mice (Fig. 2A) or females
of either genotype (Fig. 2B). However, this interaction
between sex and treatment just missed the criterion for
signiﬁcance (sex treatment interaction: F(2,60)=2.73,
P=0.073).
Captopril did not affect any of the ‘anxiety-like’ beha-
viours of either genotype, at either dose (Table 1).
3.3. AT1 receptor antagonism by losartan
increases locomotor activity in NK1R/ mice,
only
Locomotor activity was greater, overall, in NK1R/ mice
compared with wildtypes (main effect of genotype:
F(1,30)=66.72; Po0.001). An overall effect of losartan on
locomotor activity just missed the criterion for signiﬁcance
(main effect of treatment: F(2,30)=2.88; P=0.072).Post-hoc analyses revealed that, in contrast to captopril,
both doses of losartan increased the locomotor activity of
NK1R/ mice (LSD (cf., vehicle): P=0.049 (10 mg/kg)
and P=0.015 (25 mg/kg); Fig. 3A) but did not affect that of
wildtype mice.
Losartan did not affect any of the ‘anxiety-like’ beha-
viours of either genotype, at either dose (Table 1).3.4. AT2 receptor antagonism by PD 123319 does
not affect locomotor activity of NK1R/ or
wildtype mice
Again, locomotor activity was greater, overall, in NK1R/
mice compared with wildtypes (main effect of genotype: F
(1,24)=29.51; Po0.001). There was also an overall effect
of PD 123319 on locomotor activity (main effect of treat-
ment: F(2,24)=3.99; P=0.032). Post-hoc analyses revealed
that, as with losartan, both doses of PD 123319 increased
the locomotor activity of NK1R/ mice (LSD (cf. vehicle):
P=0.01 (1 mg/kg) and P=0.013 (3 mg/kg); Fig. 3B) but did
not affect that of wildtypes.
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viours of either genotype, at either dose (Table 1).3.5. The effects of the ACE inhibitor, captopril,
on the incidence of premature responses and
%omissions in the 5-CSRTT
All mice achieved the stable baseline (Stage 6 of training)
performance criteria for testing in the 5-CSRTT.
In both the VITI and the LITI, premature responses (per
100 trials) were greater, overall, in NK1R/ mice com-
pared with wildtype mice (VITI: F(1,22)=18.77, Po0.001;
LITI: F(1,22)=10.97, P=0.003; Fig. 4A and B). In the VITI,
treatment with captopril (10 mg/kg) reduced the incidence
of premature responses in NK1R/ mice, only (LSD (cf.,
vehicle): P=0.033). In the LITI, treatment with this dose of
captopril (10 mg/kg) similarly abolished the genotype dif-
ference in premature responses, whilst treatment with the
higher dose (25 mg/kg) reduced the incidence of this
behaviour in wildtypes (LSD (cf., vehicle): P=0.012; LSD
(cf., 10 mg/kg): P=0.02) but not NK1R/ mice.
In the VITI, there were no genotype differences in
%omissions, and no effects of captopril, at any dose
(Fig. 4C). However, in the LITI, %omissions were higher,
overall, in NK1R/ mice compared with wildtypes (main
effect of genotype: F(1,22)=5.8, P=0.025; Fig. 4D). ThisFig. 2 The ACE inhibitor, captopril, reduced the locomotor
activity of male NK1R/ mice, only, in the light/dark
exploration box. Effects of captopril on locomotor activity,
measured as ‘Speed in light zone’ (LZ; lines crossed/time), of
male wildtype and NK1R/ mice (A) and female wildtype
and NK1R/ mice (B). Bars indicate mean7s.e.m. Lines
indicate statistically signiﬁcant differences between groups.
* Po0.05, ** Po0.01, *** Po0.001. N=6 per group. Data were
analysed using single measures three-way ANOVA followed by
post hoc (LSD) pair-wise comparisons. Veh, vehicle; Cap10,
10 mg/kg captopril; Cap25, 25 mg/kg captopril.
Table 1 Captopril, losartan and PD 123319 did not affect a
when tested in the light/dark exploration box. Values indicate
Behaviour Captopril
Time in LZ (s) F(2,60)=0.41; P=0.666
Latency to leave LZ (s) F(2,60)=0.5; P=0.609
Latency to ﬁrst return to LZ (s) F(2,60)=0.22; P=0.803
Number of returns to LZ (s) F(2,60)=1.96; P=0.149genotype difference was abolished in mice given the inter-
mediate dose of captopril (10 mg/kg).
There were no genotype differences in perseveration in
either the VITI or the LITI, and captopril did not affect this
behaviour, in either test (Fig. 4E and F).3.6. Other behaviours in the 5-CSRTT
There was no genotype difference in total trials in either the
VITI or the LITI, and this behaviour was unaffected by captopril
(Fig. 5A and B). Latency to correct response also did not differ in
the two genotypes in either test but, in the VITI, captopril
(10 mg/kg) slightly (c. 0.05 s) increased this latency to respond
in wildtype mice, only (F(4,72)=2.72, P=0.036; LSD: P=0.042;
Fig. 5C and D). Latency to collect the reward was greater in
NK1R/ mice in both tests (VITI: F(1,21)=8.24, P=0.009;
LITI: F(1,21)=8.32, P=0.009; Fig. 5E and F). However, in the
VITI, captopril (10 mg/kg) increased the latencies of wildtypes
and abolished the genotype difference in this measure (genoty-
pe treatment interaction: F(4,69)=3.13, P=0.02). %Accuracy
in both tests was slightly lower, overall, in NK1R/ mice
(VITI: F(1,22)=14.75, Po0.001; LITI: F(1,22)=22.08, Po0.001)
(Fig. 5G and H). Captopril did not affect %accuracy in the VITIny of the ‘anxiety-like’ behaviours in the two genotypes
overall effect of treatment (drug). LZ, light zone.
Losartan PD 123319
F(2,30)=1.36; P=0.271 F(2,24)=0.84; P=0.445
F(2,30)=0.43; P=0.656 F(2,24)=0.45; P=0.645
F(2,30)=0.16; P=0.856 F(2,22)=1.92; P=0.17
F(2,30)=1.35; P=0.274 F(2,24)=0.08; P=0.924
Fig. 3 The AT1 receptor antagonist, losartan, and the AT2
receptor antagonist, PD 123319, increased the locomotor
activity of male NK1R/ mice in the light/dark exploration
box. Effects of losartan on the locomotor activity, measured as
‘Speed in light zone’ (LZ; lines crossed/time), of male wildtype
and NK1R/ mice (A). Effects of PD 123319 on the locomotor
activity, measured as ‘Speed in light zone (LZ)’ (lines crossed/
time), of male wildtype and NK1R/ mice (B). Bars indicate
mean7s.e.m. Lines indicate statistically signiﬁcant differences
between groups. * Po0.05, ** Po0.01, *** Po0.001. N=5–6 per
group. Data were analysed using single measures two-way
ANOVA followed by post hoc (LSD) pair-wise comparisons.
Veh, vehicle; Los10, 10 mg/kg losartan; Los25, 25 mg/kg losar-
tan; PD1, 1 mg/kg PD 123319; PD3, 3 mg/kg PD 123319.
Fig. 4 The angiotensin converting enzyme inhibitor, capto-
pril, improved the performance (impulsivity and inattentive-
ness) of NK1R/ mice in the 5-choice serial reaction-time
task. Effects of captopril on: premature responses (per 100
trials) in the VITI (A) and LITI (B); %omissions in the VITI (C) and
LITI (D); perseveration in the VITI (E) and LITI (F). Bars indicate
mean7s.e.m. Lines indicate statistically signiﬁcant differences
between groups. * Po0.05, ** Po0.01, *** Po0.001. N=9–12
per group. Data were analysed using mixed model three-way
ANOVA followed by post hoc (LSD) pair-wise comparisons. NI, no
injection; Veh, vehicle; Cap5, 5 mg/kg captopril; Cap10,
10 mg/kg captopril; Cap25, 25 mg/kg captopril.
Fig. 5 The effects of the angiotensin converting enzyme
inhibitor, captopril, on the performance of wildtype and
NK1R/ mice in the 5-choice serial reaction-time task:
total trials, accuracy and latencies. Effects of captopril on:
total trials in the VITI (A) and LITI (B); latency to correct response
in the VITI (C) and LITI (D); latency to collect reward in the VITI
(E) and LITI (F); %accuracy in the VITI (G) and LITI (H). Bars indicate
mean7s.e.m. Lines indicate statistically signiﬁcant differences
between groups. * Po0.05, ** Po0.01, *** Po0.001. N=9–12 per
group. Data were analysed using mixed model three-way ANOVA
followed by post hoc (LSD) pair-wise comparisons. NI, no injection;
Veh, vehicle; Cap5, 5 mg/kg captopril; Cap10, 10 mg/kg captopril;
Cap25, 25 mg/kg captopril.
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reduced this index of attention (c. 3%) in NK1R/ mice.
4. Discussion
We have investigated further the behavioural abnormalities
of inbred NK1R/ mice.
4.1. Sex differences in the locomotor activity of
NK1R/ mice
The ﬁrst aim of this study was to establish whether the
locomotor hyperactivity of male NK1R/ mice, which we
have reported previously (Fisher et al., 2007; Herpfer et al.,2005; Yan et al., 2010), is also evident in female NK1R/
mice. Whereas male NK1R/ mice were hyperactive com-
pared with their wildtype counterparts, the locomotor activity
of female NK1R/ mice did not differ from wildtypes.
This ﬁnding is potentially important because there are clear
differences in the symptom proﬁle of male and female ADHD
patients: males more commonly present as the predominantly
A.J. Porter et al.518hyperactive/impulsive or combined subtype, whereas females
typically express the predominantly inattentive subtype
(Staller and Faraone, 2006). Males with ADHD also have a
higher incidence of other externalised disruptive behaviours
(Rucklidge, 2010) and are more susceptible to disorders of
excitability and movement, such as Tourette’s syndrome or
Parkinson’s disease (Haaxma et al., 2007; Shulman, 2007). The
possibility that impaired TACR1 function contributes to these
abnormalities merits further investigation.
Motor function is regulated by dopaminergic corticostriatal
circuitry, and extensive evidence points to disruption of these
networks in ADHD (see: del Campo et al., 2011). These circuits
are modulated by gonadal steroids, during both perinatal
development and puberty, and display sexual differentiation
in male and female brains (Waddell and McCarthy, 2012). For
instance, sex differences in the distribution and density of
dopamine D1 and D2 receptors have been observed in the
nucleus accumbens, dorsal striatum and prefrontal cortex of
juvenile rats, with females experiencing smaller increases in
receptor expression during puberty than males (Anderson and
Teicher, 2000). It is argued that over-expression of dopamine
receptors, when coupled with pre-existing abnormalities in
monoaminergic transmission observed in patients with ADHD,
could contribute to the greater hyperactivity observed in male
patients, compared with females (Waddell and McCarthy,
2012). There is extensive evidence to suggest that a lack of
functional NK1R also disrupts dopaminergic transmission in
corticostriatal regions (reviewed by: Stanford, 2014). Findings
reported here suggest that a functional deﬁcit in NK1R, and, by
inference, polymorphisms of the TACR1 gene, could contribute
to sex differences in expression of hyperactivity in ADHD.4.2. Angiotensin converting enzyme and the
regulation of motor function
The second aim of this study was to determine the effects of
the angiotensin converting enzyme (ACE) inhibitor, capto-
pril, on the locomotor activity of NK1R/ mice. This was
prompted by evidence that substance P, the preferred
ligand for NK1R, is metabolised by ACE (Skidgel et al.,
1984). On this basis, it was predicted that captopril, by
increasing the availability of substance P, would reduce the
locomotor activity of wildtype mice but leave NK1R/
mice unaffected. Contrary to this prediction, captopril
prevented the hyperactivity of male NK1R/ mice with-
out affecting the locomotor activity of wildtypes. This
genotype-speciﬁc response to captopril suggests that loco-
motor hyperactivity, caused by a lack of functional NK1R in
male mice, can be prevented by reducing ACE activity. This
effect cannot be explained by increased activation of NK1R
by substance P because this peptide would be ineffective in
NK1R/ mice. Nonetheless, there are several alternative
explanations for this response to captopril. The most
obvious of these is the prevention of angiotensin II (AngII)
production, which is formed from the hydrolysis of angio-
tensin I (AngI) by ACE. Although published ﬁndings are
somewhat inconsistent, there are several reports that
intracerebroventricular administration of AngII increases
locomotor activity (see: Braszko, 2002 and references
therein), which is in line with the reduction in hyperactivity
in captopril-treated mice found here.A further interesting ﬁnding was that captopril inﬂuenced
the locomotor activity of male, but not female, NK1R/
mice. The inference that there are sex differences in the
inﬂuence of ACE on motor function is in line with evidence
that gonadal steroids inﬂuence the activity of ACE, which is
increased by testosterone and reduced by oestrogen
(Komukai et al., 2010). Indeed, low baseline levels of ACE
could explain why, in our experiment, captopril was inef-
fective in females. A difference in baseline activity of ACE
in male and female animals could also have implications for
sex differences in hyperactivity in ADHD, as well as its
potential amelioration by captopril.
To test whether or not the effect of captopril in male
NK1R/ mice was due to a reduction in AngII, we went on
to investigate the effects of the AT1 receptor antagonist,
losartan, and the AT2 receptor antagonist, PD 123319, on
the locomotor activity of the two genotypes. We reasoned
that, if the prevention of hyperactivity of NK1R/ mice
by captopril is due to a reduction in AngII availability, then
that response to captopril should be mimicked by antagon-
ism of AT1 receptors and/or AT2 receptors. In fact, both
AngII receptor antagonists increased, rather than reduced,
the locomotor activity of NK1R/ mice, but neither
compound affected wildtype mice.
Previous reports concerning the effects of AngII receptor
antagonism on locomotor activity are somewhat inconsis-
tent. In studies of male outbred Wistar rats, losartan and
PD 123319 were both ineffective when administered alone
(Braszko, 2002). Losartan was also ineffective in the spon-
taneously hypertensive rat, the most extensively studied
rodent model of ADHD (Irvine et al., 1995). Although these
results are consistent with the lack of effect of either
antagonist in wildtypes seen here, in another study, losartan
decreased locomotor activity in outbred BALB/c mice
(Raghavendra et al., 1998). Both losartan and PD 123319
also abolished an increase in locomotor activity following
intracerebroventricular administration of AngII in rats
(Braszko, 2002).
All of these ﬁndings stand in contrast to the increase in
locomotor activity of NK1R/ mice, following administra-
tion of losartan and PD 123319, in this study. Nevertheless, our
ﬁndings suggest that the inﬂuence of angiotensin receptors on
motor function is disrupted in these mice, which again points
to a functional interaction between the BRAS and NK1R in the
regulation of motor activity.
The proposal that both ACE and AngII receptors are involved
in the regulation of motor function is supported by their high
densities in both the striatum and the substantia nigra, albeit
with different distributions. Speciﬁcally, angiotensin receptors
are found on nigrostriatal dopaminergic nerve terminals (Allen
et al., 1992), whereas the density of ACE is highest on
striatonigral and striatopallidal neurons (Chai et al., 1987).
There is also evidence that ACE inhibition increases striatal
dopamine efﬂux (Jenkins, 2008), which could underlie its
inﬂuence on locomotor activity. This is an interesting possibility
because captopril increases the striatal concentration of the
substance P metabolic fragment, substance P(1–7) (Michael-Titus
et al., 2002), which increases striatal dopamine release in a
concentration-dependent manner (Reid et al., 1990). Impor-
tantly, this dopamine response is mediated by an NK1R-
independent mechanism and so could occur in NK1R/ mice.
Nevertheless, several other neuropeptides (e.g., bradykinin,
519The angiotensin converting enzyme inhibitor, captopril,neurotensin, dynorphin and enkephalin), are also metabolised
by ACE (Skidgel et al., 1984). It cannot be ruled out that changes
in the availability of any, or all, of these peptides contribute to
the behavioural response to captopril.
Whatever the mechanism, it is clear that any change in
locomotor activity triggered by either ACE inhibitors, or
AngII receptor antagonists, is prevented by functional NK1R.
This ﬁnding could be exploited therapeutically because it
suggests that ACE inhibition could be beneﬁcial in reducing
the hyperactivity of (male) ADHD patients with polymorph-
ism of the TACR1 gene.4.3. Angiotensin converting enzyme and
impulsivity/inattention in the 5-CSRTT
The third aim of this study was to determine whether captopril
would improve the cognitive performance of NK1R/ mice in
the 5-CSRTT. This seems to be the case because captopril dose-
dependently abolished the genotype difference in premature
responses in both the VITI and the LITI test, as well as the
genotype difference in omissions in the LITI test. Neither of
these responses is likely to be explained by any change in
motivation to carry out the task because, in NK1R/ mice,
captopril did not reduce total trials or increase either the
latency to correct response or latency to collect the reward. We
also do not believe that the lack of any change in %omissions in
the VITI is due to a ﬂoor effect because, in a previous study
using this test, treatment with guanfacine reduced this measure
in NK1R/ mice, only (Pillidge et al., 2014).
There are many reports that ACE inhibitors improve cogni-
tive performance (for review, see: Wright and Harding, 2011)
but this is the ﬁrst instance of such a drug being tested in the
5-CSRTT. The mechanisms underlying this effect are, as yet,
unknown. However, as with motor activity, the response to
captopril in this test cannot be explained by an increase in
substance P transmission. Instead, functional changes in any of
a range of neuropeptides could contribute to the response to
captopril in NK1R/ mice (see above). Another possibility,
not explored here, is that the improved cognitive performance
is mediated by the AngII fragment angiotensin IV, which
activates angiotensin type 4 (AT4) receptors (see: Wright and
Harding, 2011). It is also striking that the improvements in
premature responses seen in NK1R/ mice treated with
captopril showed a bell-shaped dose-dependent response. This
bears similarities to that of other drugs that are used to treat
ADHD, such as methylphenidate, which can show beneﬁcial
effects at low but not higher doses (Tannock et al., 1995).
Impulsivity is widely believed to be associated with
abnormal serotonergic transmission, dopaminergic transmis-
sion, or both (Oades, 2002), whereas impaired attention
points more speciﬁcally to disruption of noradrenergic
transmission (Aston-Jones and Cohen, 2005). Although there
are limited reports directly investigating the effects of
captopril on the function of these neurotransmitters, there
is considerable indirect evidence to suggest that ACE
inhibition would affect all three of these systems: neuro-
peptides that are metabolised by ACE affect the function of
serotonin (Jenkins, 2008), dopamine (Prus et al., 2007) and
noradrenaline (Sumners and Phillips, 1983) in neuronal
networks implicated in ADHD. To the best of our knowledge,
the results of this study offer the ﬁrst evidence that theBRAS inﬂuences premature responses and that this abnormal
behaviour is diminished by captopril, and possibly other ACE
inhibitors. The effects of ACE inhibitors on the function of
neuronal networks that inﬂuence this form of impulsivity
warrant further investigation, especially in ADHD patients.
4.4. Conclusions
Here, we report that the hyperactivity of male NK1R/
mice is not evident in female mice, revealing striking parallels
between this abnormal behaviour and differences in the typical
symptom proﬁle of male and female patients with ADHD. We
also report that the ACE inhibitor, captopril, prevents the
hyperactivity, impulsivity and, possibly, inattentiveness, of
male NK1R/ mice. These ﬁndings point to a functional
interaction between the BRAS and NK1R on these behaviours
that merits further investigation. Our ﬁndings further suggest
that captopril (and possibly other ACE inhibitors) could provide
a novel therapeutic target for the treatment of ADHD,
particularly in males expressing the Predominantly Hyperac-
tive/Impulsive Subtype of this disorder.
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